T-E Pharma Revenue
Biotechnology Research • 
Taipei, Taiwan, Province of China • 1-10 Employees
T-E Pharma revenue & valuation
| Annual revenue | $769,995 |
| Revenue per employee | $86,000 |
| Estimated valuation?This valuation is estimated based on industry average for the Biotechnology Research industry and current estimated revenues | $2,500,000 |
| Total funding | No funding |
Key Contact at T-E Pharma
Art Hsing-Mao Chu
Vice President of Research and Development
Company overview
| Headquarters | Taipei, Taiwan, Province of China |
| Phone number | +886226512268 |
| Website | |
| SIC | 873 |
| Keywords | Biotechnology, Bioconjugation, Antibody-Drug Conjugate, Multi-Arm Linkers, Radioimmunotherapy, Therapeutic Peptides |
| Founded | 2014 |
| Employees | 1-10 |
| Socials |
T-E Pharma Email Formats
T-E Pharma uses 2 email formats. The most common is {first initial}.{last name} (e.g., j.doe@immunwork.com), used 66.7% of the time.
| Format | Example | Percentage |
|---|---|---|
{first initial}.{last name} | j.doe@immunwork.com | 66.7% |
{first name}.{last name} | john.doe@immunwork.com | 33.3% |
About T-E Pharma
T-E Pharma Holding owns two subsidiaries: Immunwork, Inc. and T-E Meds, Inc. Immunwork, Inc. (https://www.immunwork.com/) founded in 2014, is dedicated to the research, development and commercialization of innovative therapeutics based on our proprietary “T-ETM pharmaceuticals” platform. The drug-design platform is employed in the construction of ultra-long-acting peptide therapeutics, antibody-drug conjugates (ADCs), antibody-radionuclide conjugates (ARCs), and other advanced pharmaceutical modalities. To focus development efforts in the ADC/ARC field, Immunwork established T-E Meds, Inc. in 2022 to take over and further develop its ADC and ARC platforms and associated drug candidates. Among our leading clinical assets, TE-8214 and TE-8105, both developed using its ultra-long-acting platform, represent key milestones. TE-8214, targeting neuroendocrine tumors and acromegaly, successfully completed its Phase I trial in June 2025. TE-8105, aimed at treating obesity (including weight management), type 2 diabetes, and fatty liver disease, is expected to complete its Phase I/IIA trial in October 2025. Both candidates have demonstrated good tolerability with no significant side effects. Phase II trials are currently in active preparation. T-E Meds, Inc. (https://www.temeds.com/) founded in 2022, focuses exclusively on antibody-drug conjugates (ADCs) and antibody-radionuclide conjugates (ARCs). Unlike conventional ADC/ARC platforms that often suffer from low product homogeneity and complex manufacturing processes, T-E Meds employs a proprietary bioconjugation platform that enables streamlined, enzyme-free, site-specific conjugation. This approach yields homogeneous ADCs/ARCs with high drug-to-antibody ratio (DAR), excellent yield, high purity, and flexible payload incorporation. T-E Meds is advancing a robust pipeline of preclinical candidates targeting various cancers, with IND filings for lead candidate planned in 2026 H1.
Employees by Management Level
Total employees: 1-10
Seniority
Employees
Funding Data
T-E Pharma has never raised funding before.
T-E Pharma Tech Stack
Discover the technologies and tools that power T-E Pharma's digital infrastructure, from frameworks to analytics platforms.
JavaScript libraries
JavaScript libraries
Tag managers
Font scripts
JavaScript libraries
Font scripts
JavaScript libraries
Miscellaneous
SSL/TLS certificate authorities
JavaScript libraries
JavaScript libraries
United States
Canada
Ireland
Australia
ItalyFrequently asked questions
4.8
40,000 users
